← H B Fuller overview

H B Fuller vs Axalta Coating Systems: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

H B Fuller Company (FUL)

Q3 2026
▲2▼1

Fuller's profit jumps, AMS deal and Ancora bid reshape outlook

  • Strong profit growth and pricing Q2 profit rose 19% to $1.41 per share and Q3 profit jumped 21% to $1.52 per share, helped by 7.4% higher prices. All business units grew and profit margins expanded.

    This is the core positive driver of the quarter, showing broad-based earnings strength.

  • Advanced Medical Solutions acquisition Fuller is buying Advanced Medical Solutions for £715 million, moving into higher-growth medical adhesives. This expands its healthcare business and could boost future sales and profits.

    A major strategic move that shifts the company toward faster-growing markets.

  • Ancora's bid for Building Adhesives unit Activist investor Ancora raised its offer for Fuller's Building Adhesives unit to $1.4 billion. The public fight highlights that the unit may be undervalued, but it also creates uncertainty about the company's future structure.

    This event signals potential value but also introduces uncertainty, making it a mixed driver.

  • Rising debt and borrowing costs The AMS deal pushes debt to about 4 times earnings. Fuller also priced $850 million in 7.625% senior notes and refinanced $420 million, meaning higher interest costs that could squeeze future profits and increase financial risk.

    This is the main risk weighing on the stock, as higher debt and interest expenses could pressure earnings.

August 2026
▲1▼1

Fuller's profit engine hums, but debt and a buyout fight weigh

  • Q3 profit jumps 21% on pricing power Fuller's third-quarter profit rose 21% to $1.52 a share, beating estimates, as 7.4% price increases offset lower volumes. All three business units grew, and margins expanded. This shows the core adhesives business is getting stronger, which supports a higher stock price.

    This is the main new fundamental driver of FUL's value this period.

  • Ancora raises bid for building adhesives unit to $1.4B Activist Ancora lifted its cash offer for Fuller's Building Adhesives unit to as much as $1.4 billion, about half Fuller's market value, after the board rejected its earlier bid. The board says the unit is worth more. A sale could unlock value, but the public fight adds uncertainty.

    The raised bid is a major new event that could reshape the company and its stock.

  • AMS acquisition advances but adds debt risk Advanced Medical Solutions shareholders approved Fuller's £715 million purchase, moving the medical-adhesives deal closer to closing by year-end. It should boost long-term growth, but will push debt to about 4 times earnings, and analysts trimmed fair value on execution risk.

    The deal's progress and its balance-sheet impact are key new developments.

  • High-cost debt refinancing and new notes Fuller refinanced $420 million of loans and priced $850 million of 7.625% senior notes due 2034. The high interest rate signals lenders demand a premium, raising future interest costs and squeezing profits. This weighs on the stock by increasing financial risk.

    The expensive new debt is a fresh negative for FUL's finances.

Latest
▲1▼1

Fuller's profit engine hums, but debt and a buyout fight weigh

  • Q3 profit jumps 21% on pricing power Fuller's third-quarter profit rose 21% to $1.52 a share, beating estimates, as 7.4% price increases offset lower volumes. All three business units grew, and margins expanded. This shows the core adhesives business is getting stronger, which supports a higher stock price.

    This is the main new fundamental driver of FUL's value this period.

  • Ancora raises bid for building adhesives unit to $1.4B Activist Ancora lifted its cash offer for Fuller's Building Adhesives unit to as much as $1.4 billion, about half Fuller's market value, after the board rejected its earlier bid. The board says the unit is worth more. A sale could unlock value, but the public fight adds uncertainty.

    The raised bid is a major new event that could reshape the company and its stock.

  • AMS acquisition advances but adds debt risk Advanced Medical Solutions shareholders approved Fuller's £715 million purchase, moving the medical-adhesives deal closer to closing by year-end. It should boost long-term growth, but will push debt to about 4 times earnings, and analysts trimmed fair value on execution risk.

    The deal's progress and its balance-sheet impact are key new developments.

  • High-cost debt refinancing and new notes Fuller refinanced $420 million of loans and priced $850 million of 7.625% senior notes due 2034. The high interest rate signals lenders demand a premium, raising future interest costs and squeezing profits. This weighs on the stock by increasing financial risk.

    The expensive new debt is a fresh negative for FUL's finances.

July 2026
▲2

Fuller's profit beat and buyout battle reshape its path

  • Strong Q2 earnings and raised guidance Fuller's second-quarter profit rose 19% to $1.41 per share, revenue grew 5.8%, and the company raised its full-year profit outlook. This shows the core business is performing well, which supports a higher stock price.

    This is the main positive fundamental driver for FUL's price this period.

  • Acquisition of Advanced Medical Solutions Fuller agreed to buy Advanced Medical Solutions for £715 million, moving into higher-growth medical adhesives. The deal should boost long-term growth but will temporarily raise debt to about 4 times earnings, and an activist investor opposes it.

    This is a major strategic move that affects FUL's growth and risk profile.

  • Ancora's buyout offer for building adhesives unit Ancora offered $1.1–1.2 billion for Fuller's Building Adhesives Solutions unit, but the board rejected it as too low. The offer highlights the unit's value and could pressure management to unlock it, potentially lifting the stock.

    This event shows external interest in Fuller's assets and could lead to value creation.

▲2

Fuller's profit beat and buyout battle reshape its path

  • Strong Q2 earnings and raised guidance Fuller's second-quarter profit rose 19% to $1.41 per share, revenue grew 5.8%, and the company raised its full-year profit outlook. This shows the core business is performing well, which supports a higher stock price.

    This is the main positive fundamental driver for FUL's price this period.

  • Acquisition of Advanced Medical Solutions Fuller agreed to buy Advanced Medical Solutions for £715 million, moving into higher-growth medical adhesives. The deal should boost long-term growth but will temporarily raise debt to about 4 times earnings, and an activist investor opposes it.

    This is a major strategic move that affects FUL's growth and risk profile.

  • Ancora's buyout offer for building adhesives unit Ancora offered $1.1–1.2 billion for Fuller's Building Adhesives Solutions unit, but the board rejected it as too low. The offer highlights the unit's value and could pressure management to unlock it, potentially lifting the stock.

    This event shows external interest in Fuller's assets and could lead to value creation.

Axalta Coating Systems Ltd (AXTA)

Q3 2026
▲3

Axalta's Akzo merger clears EU hurdle as earnings stay strong

  • EU regulators set to clear Akzo deal with divestments AkzoNobel will sell overlapping vehicle-refinish businesses to satisfy EU regulators, who are expected to approve the $25 billion all-stock merger; the powder-coating concern was dropped. Removing this regulatory block makes the deal far more likely to close, supporting AXTA's price.

    This is the biggest new force: the merger's key regulatory hurdle is being cleared.

  • Q2 beat: record EBITDA, revenue and EPS above estimates Axalta posted record quarterly adjusted EBITDA of $305 million at a 22.7% margin, revenue up 3.1% to $1.35 billion and EPS of $0.72, both beating estimates, with Refinish and Mobility growing. Strong results and maintained guidance support the stock.

    The quarter's results are the core fundamental driver behind the shares.

  • Governance sweeteners and Akzo's own profit growth After shareholder talks, the combined company will hold annual director elections and lower a key approval threshold to two-thirds. AkzoNobel also reported higher Q2 profit and said the merger is on track, with a shareholder vote set for August 5.

    These steps reduce deal risk and show the partner is financially healthy.

  • Fairness probe and valuation debate temper the good news A law firm is investigating whether Axalta's shareholders get a fair deal, which could pressure terms. Meanwhile one valuation model calls the stock about 30% overvalued near $35.81, while a cash-flow model sees it far higher, so views on worth are split.

    This is the real counterweight: legal risk to the deal and disagreement over what the shares are worth.

August 2026
▲3

Axalta's Akzo merger clears EU hurdle as earnings stay strong

  • EU regulators set to clear Akzo deal with divestments AkzoNobel will sell overlapping vehicle-refinish businesses to satisfy EU regulators, who are expected to approve the $25 billion all-stock merger; the powder-coating concern was dropped. Removing this regulatory block makes the deal far more likely to close, supporting AXTA's price.

    This is the biggest new force: the merger's key regulatory hurdle is being cleared.

  • Q2 beat: record EBITDA, revenue and EPS above estimates Axalta posted record quarterly adjusted EBITDA of $305 million at a 22.7% margin, revenue up 3.1% to $1.35 billion and EPS of $0.72, both beating estimates, with Refinish and Mobility growing. Strong results and maintained guidance support the stock.

    The quarter's results are the core fundamental driver behind the shares.

  • Governance sweeteners and Akzo's own profit growth After shareholder talks, the combined company will hold annual director elections and lower a key approval threshold to two-thirds. AkzoNobel also reported higher Q2 profit and said the merger is on track, with a shareholder vote set for August 5.

    These steps reduce deal risk and show the partner is financially healthy.

  • Fairness probe and valuation debate temper the good news A law firm is investigating whether Axalta's shareholders get a fair deal, which could pressure terms. Meanwhile one valuation model calls the stock about 30% overvalued near $35.81, while a cash-flow model sees it far higher, so views on worth are split.

    This is the real counterweight: legal risk to the deal and disagreement over what the shares are worth.

Latest
▲3

Axalta's Akzo merger clears EU hurdle as earnings stay strong

  • EU regulators set to clear Akzo deal with divestments AkzoNobel will sell overlapping vehicle-refinish businesses to satisfy EU regulators, who are expected to approve the $25 billion all-stock merger; the powder-coating concern was dropped. Removing this regulatory block makes the deal far more likely to close, supporting AXTA's price.

    This is the biggest new force: the merger's key regulatory hurdle is being cleared.

  • Q2 beat: record EBITDA, revenue and EPS above estimates Axalta posted record quarterly adjusted EBITDA of $305 million at a 22.7% margin, revenue up 3.1% to $1.35 billion and EPS of $0.72, both beating estimates, with Refinish and Mobility growing. Strong results and maintained guidance support the stock.

    The quarter's results are the core fundamental driver behind the shares.

  • Governance sweeteners and Akzo's own profit growth After shareholder talks, the combined company will hold annual director elections and lower a key approval threshold to two-thirds. AkzoNobel also reported higher Q2 profit and said the merger is on track, with a shareholder vote set for August 5.

    These steps reduce deal risk and show the partner is financially healthy.

  • Fairness probe and valuation debate temper the good news A law firm is investigating whether Axalta's shareholders get a fair deal, which could pressure terms. Meanwhile one valuation model calls the stock about 30% overvalued near $35.81, while a cash-flow model sees it far higher, so views on worth are split.

    This is the real counterweight: legal risk to the deal and disagreement over what the shares are worth.